These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 3461211)

  • 1. Effect of DL-buthionine-S,R-sulfoximine on the growth of EMT6 and RIF mouse tumors.
    Miller AC; Henderson BW
    J Natl Cancer Inst; 1986 Aug; 77(2):505-10. PubMed ID: 3461211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of glutathione depletion by L-buthionine sulfoximine on the cytotoxicity of cyclophosphamide in single and fractionated doses to EMT6/SF mouse tumors and bone marrow.
    Ono K; Shrieve DC
    J Natl Cancer Inst; 1987 Oct; 79(4):811-5. PubMed ID: 3477662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemosensitization of L-phenylalanine mustard by the thiol-modulating agent buthionine sulfoximine.
    Kramer RA; Greene K; Ahmad S; Vistica DT
    Cancer Res; 1987 Mar; 47(6):1593-7. PubMed ID: 3815359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of buthionine sulfoximine (NSC 326231) and its effect on melphalan-induced toxicity in mice.
    Smith AC; Liao JT; Page JG; Wientjes MG; Grieshaber CK
    Cancer Res; 1989 Oct; 49(19):5385-91. PubMed ID: 2766304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of buthionine sulfoximine and misonidazole on glutathione level and radiosensitivity of human tumor xenografts.
    Guichard M; Lespinasse F; Malaise EP
    Radiat Res; 1986 Jan; 105(1):115-25. PubMed ID: 3945723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of murine phenytoin teratogenicity by the gamma-glutamylcysteine synthetase inhibitor L-buthionine-(S,R)-sulfoximine and by the glutathione depletor diethyl maleate.
    Wong M; Helston LM; Wells PG
    Teratology; 1989 Aug; 40(2):127-41. PubMed ID: 2772848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced melphalan cytotoxicity following buthionine sulfoximine-mediated glutathione depletion in a human medulloblastoma xenograft in athymic mice.
    Skapek SX; Colvin OM; Griffith OW; Elion GB; Bigner DD; Friedman HS
    Cancer Res; 1988 May; 48(10):2764-7. PubMed ID: 3359437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Augmentation of cisplatin (DDP) cytotoxicity in vivo by DL-buthionine sulfoximine (BSO) in DDP-sensitive and-resistant rat ovarian tumors and its relation to DNA interstrand cross links.
    Chen G; Zeller WJ
    Anticancer Res; 1991; 11(6):2231-7. PubMed ID: 1776864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glutathione depletion by DL-buthionine-SR-sulfoximine (BSO) potentiates X-ray-induced chromosome lesions after liquid holding recovery.
    Bertsche U; Schorn H
    Radiat Res; 1986 Mar; 105(3):351-69. PubMed ID: 3754339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of glutathione depletion by buthionine sulfoximine on radiosensitization by oxygen and misonidazole in vitro.
    Shrieve DC; Denekamp J; Minchinton AI
    Radiat Res; 1985 Jun; 102(3):283-94. PubMed ID: 4070545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. d,l-buthionine-(S,R)-sulfoximine potentiates in vivo the therapeutic efficacy of doxorubicin against multidrug resistance protein-expressing tumors.
    Vanhoefer U; Cao S; Minderman H; Toth K; Skenderis BS; Slovak ML; Rustum YM
    Clin Cancer Res; 1996 Dec; 2(12):1961-8. PubMed ID: 9816155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glutathione depletion by L-buthionine sulfoximine antagonizes taxol cytotoxicity.
    Liebmann JE; Hahn SM; Cook JA; Lipschultz C; Mitchell JB; Kaufman DC
    Cancer Res; 1993 May; 53(9):2066-70. PubMed ID: 8097674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SR-2508 plus buthionine sulfoximine or SR-2508 alone: effects on the radiation response and the glutathione content of a human tumor xenograft.
    Lespinasse F; Biscay P; Malaise EP; Guichard M
    Radiat Res; 1987 Apr; 110(1):149-54. PubMed ID: 2951766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined effects of buthionine sulfoximine and cepharanthine on cytotoxic activity of doxorubicin to multidrug-resistant cells.
    Kisara S; Furusawa S; Murata R; Ogata M; Hikichi N; Takayanagi Y; Sasaki K
    Oncol Res; 1995; 7(3-4):191-200. PubMed ID: 8555653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of L-buthionine-[S,R]-sulfoximine on the pancreas in mice. A model of weakening glutathione-based defense mechanisms.
    Lüthen RE; Neuschwander-Tetri BA; Niederau C; Ferrell LD; Grendell JH
    Int J Pancreatol; 1994 Aug; 16(1):31-6. PubMed ID: 7528760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Buthionine sulfoximine enhances glutathione-but attenuates glutamate-stimulated cell proliferation.
    Kang YJ
    Cell Mol Biol Res; 1995; 41(2):131-6. PubMed ID: 8581064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Establishment of a melphalan-resistant rhabdomyosarcoma xenograft with cross-resistance to vincristine and enhanced sensitivity following buthionine sulfoximine-mediated glutathione depletion.
    Rosenberg MC; Colvin OM; Griffith OW; Bigner SH; Elion GB; Horton JK; Lilley E; Bigner DD; Friedman HS
    Cancer Res; 1989 Dec; 49(24 Pt 1):6917-22. PubMed ID: 2582434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxic effects of acute glutathione depletion by buthionine sulfoximine and dimethylfumarate on murine mammary carcinoma cells.
    Dethlefsen LA; Lehman CM; Biaglow JE; Peck VM
    Radiat Res; 1988 May; 114(2):215-24. PubMed ID: 3375425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancement of EMT6/SF tumor cell killing by mitomycin C and cyclophosphamide following in vivo administration of buthionine sulfoximine.
    Ono K; Shrieve DC
    Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1175-8. PubMed ID: 3091546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell cycle progression of glutathione-depleted human peripheral blood mononuclear cells is inhibited at S phase.
    Messina JP; Lawrence DA
    J Immunol; 1989 Sep; 143(6):1974-81. PubMed ID: 2789253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.